An observational study in Acute Heart Failure (AHF), sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Heart Failure by Assiut University — 12 open to participants now, 12 under way, none of them phase 3. Heart Failure · Assiut University.
Among the 23 studies in Heart Failure by Assiut University, this one has the largest planned enrollment of the 20 observational ones that give a count, is one of 5 that started in 2026, is one of 20 observational ones, reaches primary completion later than 11 of the 11 other live ones, and was the 19th registered.
6,332 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →12 of the 23 studies in Heart Failure by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University
Ages 18–65
Assiut University
Ages 18+
Assiut University
Ages 18+
Assiut University
Ages 18+
Assiut University
Ages 18+
By country, each count listing its studies:
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 200 across 1,983 observational studies indexed under Heart Failure.
Median enrollment 100 across the 3 interventional studies, 100 across the 20 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,081 studies on the registry; 2,179 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
5 of the studies in Heart Failure by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07277140Assiut UniversityImpact of Iron Deficiency on Arrhythmic Events and Resting ECG Abnormalities in Patients Hospitalized With Heart Failure | 2027-01-01 |
| NCT07821801Assiut UniversityShort-Term Outcomes of HFrEF Patients on Guideline-Directed Medical Therapy | 2027-09-10 |
| NCT07830940Assiut UniversityFinerenone and Cardiac Remodeling in HFpEF | 2027-09-25 |
| NCT07845201Assiut UniversityIntermediate Outcomes of HFrEF Patients on Guideline-Directed Medical Therapy | 2027-09-26 |
| NCT07847112Assiut UniversitySoluble TREM-1 in Diabetes-Associated Cardiovascular Complications | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 23 studies in Heart Failure by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical Characteristics, Etiology, Short-Term Outcomes, and Performance of Contemporary Risk Stratification Scores in Acute Heart Failure Patients Presenting to Assiut University Heart Hospital.
Primary Aim To characterize the demographic and clinical characteristics, etiological spectrum, precipitating factors, management, and short-term outcomes, including length of stay, ICU admission, organ failure, and 30-day rehospitalization, of patients presenting with acute heart failure at Assiut University Heart Hospital
.Secondary Aim To evaluate the prognostic performance of the HEARTRISK6 score by externally validating its ability to predict short-term adverse outcomes, including in-hospital mortality.
Acute heart failure patients presenting to Emergency Department and Cardiology Department, Assiut University Hospitals, Egypt.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Echo for clinical assessment
Twelve leads ECG to detect any ischemic changes
To detect renal function test
Ischemic changes
Clinical Characteristics, Etiology, Short-Term Outcomes, and Performance of Contemporary Risk Stratification Scores in Acute Heart Failure Patients Presenting to Assiut University Heart Hospital.
To externally validate the HEARTRISK6 score and evaluate its predictive performance for short-term adverse outcomes in patients with acute heart failure. History of moderate/severe valvular heart disease\_Yes. 1 Heart rate \>100 to ≤120 bpm. 2 \>120 bpm. 3 Non-invasive ventilation (NIV)BiPAP/NIV within first hour 2 Creatinine \>150 to ≤300 µmol/L 2 \>300 µmol/L. 3 Troponin \>3-5 × upper reference limit (URL) 1 \>5 × URL. 2 Failed reassessment / 3-minute walk test ifFailed1 comp0 High score means worse
Time frame: Follow up patients for 30 days
Plan to share: Yes
Start is estimated for Aug 2026; primary completion for Aug 2028, 24 months later.
Of 794 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 99. This study's planned 24 months is below that.
Counting every sponsor, half of 976 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.